The core technology of MBL includes monoclonal antibody (mAb) development. In order to further reinforce our core competence, we constantly work towards the advancement and challenge of antibody development technology by improving the quality of antibodies. Moreover, we actively adopt novel techniques that have originally been developed by Japanese immunologists. By focusing on innovative and unique technologies of antibody production, MBL’s business opportunities will expand beyond the continuous improvement of the quality of our own products, towards the development of novel antibodies for diagnostics, therapeutic antibodies, and revenue generating of license agreements.
Our mouse monoclonal antibody development technologies include Artificial Lymph Node Technology and Immunogenicity-Enhancing Antigen Technology. The human monoclonal antibody technology is known as SPYMEG, a novel human lymphocyte fusion partner cell line.